


IUIS Webinar: COVID-19 & Immune Compromise



In this Webinar, Kathleen Sullivan discusses how *COVID-19 impacts immunodeficient patients*.

She began her talk emphasising that majority of COVID-19 research has focused on pathogenesis, however, very limited knowledge is available on the intersections between COVID-19 and immunodeficiency. For more information on the different arms of immunity associated with COVID-19 immunity and pathology, read the articles below.

- [Is there a role of T cells in immune protection to SARS-CoV-2 infection and COVID-19?](#)
- [Cytokine Release Syndrome & COVID-19](#)
- [The current status of COVID-19 immunology](#)
- [SAIS/Immunopaedia Webinar: Antibody responses and serology testing](#)
- [The “topology” of the immune response to COVID-19](#)
- [Other COVID-19 associated articles](#)

She also cautioned on the inference of COVID-19 pathogenicity using systemic immune profiling or understanding immunity to COVID-19 and presented data that illustrated discrepancies in chemokine and cytokines expression levels between blood and lung samples.

Hodge / 2004 Aug / 105 / 1105 / 2005 05 28 / 17:00:00

The action is in the lungs.

Majority of immuno-ageing studies have focused on the reduced activity of adaptive immunity in elderly individuals which contributes to increased susceptibility to viral infections. In line with this data, ageing is one of the highest risk factors of COVID-19 severity. Kathleen also described that myeloid dysfunction is also associated with ageing. Further, she described data that showed that co-morbidities listed below were not associated with increased risk of severe COVID-19.

- **HIV (low T cell count):** Though the majority of studies show no increased risk, a study conducted in South Africa contradicts.
- **Cancer:** Studies suggested that progressive cancer disease seems to be a risk factor for COVID-19.

Cancer (Kudrer)

- | Increased risk | No additional risk |
|---|--|
| <ul style="list-style-type: none">• Age• Non-white race• Cardiac disease• Hypertension• Chronic kidney disease• Immune checkpoint inhibitor | <ul style="list-style-type: none">• Major surgery in past month• Recent chemotherapy• Metastatic disease |

- Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and/or inflammatory cytokine blockersg anti-IL-17, IL-23 or IL-12/23
- Inborn errors of immunity g Antibody deficiency

References

- Different cell types transcriptional analyses

Blanco-Melo et al., 2020, Cell 181, 1036–1045 May 28, 2020 © 2020 Elsevier Inc. <https://doi.org/10.1016/j.cell.2020.04.020>
Garrison Bioarchive doi: <https://doi.org/10.1101/2020.05.28.123889>

- Blood

Karl-Cervantes Bioarchive doi: <https://doi.org/10.1101/2020.05.18.104717>
Chevlier doi: <https://doi.org/10.1101/2020.08.04.236315>.

- HIV

- Wernke Lancet HIV doi: [https://doi.org/10.1016/S2352-3026\(20\)30164-8](https://doi.org/10.1016/S2352-3026(20)30164-8)
- Patel JV et al. Clinical outcomes by HIV serostatus, CD4 count, and viral suppression among people hospitalized with COVID-19 in the Bronx, New York. 23rd International AIDS Conference, abstract OABLB0102, 2020.
- Ho H et al. Immunologic characteristics of acute COVID-19 in people with HIV. 23rd International AIDS Conference, abstract OABLB0104, 2020.

- Davies doi: <https://doi.org/10.1101/2020.07.02.20145285>

Summary by Cheleka Mpande